Spravato™ (esketamine) – New drug approval
March 5, 2019 - The FDA announced the approval of Janssen and J&J’s Spravato (esketamine), in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.
Download PDF
